All In Biotech

Drug Trial Radar · NCT07750704

Lorlatinib Plus Sacituzumab Tirumotecan With Peripheral ctDNA Guidance as First-Line Therapy for ALK Fusion-Positive NSCLC

Lorlatinib Combined With Sacituzumab Tirumotecan Based on Peripheral Blood ctDNA as First-Line Treatment for Patients With ALK Fusion-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer: A Prospective, Open-Label, Multicenter Study

Last checked: Nov 20, 2026Latest source record: Aug 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 153 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

153

Planned (sponsor's estimate)

Start

Sep 2026

Primary completion

Sep 2029

Study completion Mar 2030

Sponsor

Lead sponsor
Guangdong Association of Clinical TrialsAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Aug 6, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This investigator-initiated, open-label, prospective Phase II clinical trial, planned to take place across multiple centers in China. We design this trial to evaluate the safety and efficacy of lorlatinib plus sacituzumab tirumotecan based on peripheral blood ctDNA as first-line treatment for ALK fusion NSCLC.

Conditions

  • ALK Positive Non-small Cell Lung Cancer

Interventions

  • LorlatinibDrug

    lorlatinib 100 mg orally once daily (QD)

  • sacituzumab tirumotecan plus lorlatinibDrug

    lorlatinib 100 mg orally once daily (QD) plus sacituzumab tirumotecan 4 mg/kg administered as an intravenous infusion on Day 1 and Day 15 of each 4-week cycle (Q4W) for 4 cycles

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. 1-year PFS rateTime frame: From date of first dosing to first documented progression or death from any cause, whichever came first, assessed up to 1 year.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Guangdong Provincial Perople's Hospital

    Guangzhou, Guangdong, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.